1160270-12-1

Basic information

• Product Name: 4-[4-(2,2,2-trifluoro-1-hydroxyethyl)phenyl]-7-[4-(trifluoromethyl)phenyl]-2-naphthoic acid
• Synonyms: 4-[4-(2,2,2-trifluoro-1-hydroxyethyl)phenyl]-7-[4-(trifluoromethyl)phenyl]-2-naphthoic acid
• CAS NO: 1160270-12-1
• Molecular Weight: 490.402
• Mol File: 1160270-12-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4-[4-(2,2,2-trifluoro-1-hydroxyethyl)phenyl]-7-[4-(trifluoromethyl)phenyl]-2-naphthoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[4-(2,2,2-trifluoro-1-hydroxyethyl)phenyl]-7-[4-(trifluoromethyl)phenyl]-2-naphthoic acid(1160270-12-1)
• EPA Substance Registry System: 4-[4-(2,2,2-trifluoro-1-hydroxyethyl)phenyl]-7-[4-(trifluoromethyl)phenyl]-2-naphthoic acid(1160270-12-1)

Safety Data

• Hazardous Substances Data: 1160270-12-1(Hazardous Substances Data)

Upstream product

• 178876-99-8 7-Bromo-4-hydroxynaphthalene-2-carboxylic acid ethyl ester 
• 128796-39-4 4-trifluoromethylphenylboronic acid 
• 1160269-99-7 ethyl 7-(4-(trifluoromethyl)phenyl)-4-hydroxy-2-naphthoate 
• 80418-12-8 1-(4-bromo-phenyl)-2,2,2-trifluoro-ethanol 
• 1160270-14-3 ethyl 7-(4-(trifluoromethyl)phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-naphthoate 
• 1160270-01-8 ethyl 7-(4-(trifluoromethyl)phenyl)-4-(((trifluoromethyl)sulfonyl)oxy)-2-naphthoate 
• 1160270-16-5 ethyl 4-[4-(2,2,2-trifluoro-1-hydroxyethyl)phenyl]-7-[4-(trifluoromethyl)phenyl]-2-naphthoate 

Downstream Products

• 1160270-20-1 4-{4-[(1S)-2,2,2-trifluoro-1-hydroxyethyl]phenyl}-7-[4-(trifluoromethyl)phenyl]-2-naphthoic acid 
• 1160270-18-7 4-{4-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]phenyl}-7-[4-(trifluoromethyl)phenyl]-2-naphthoic acid 

Relevant articles and documents

The identification of 4,7-disubstituted naphthoic acid derivatives as UDP-competitive antagonists of P2Y14

A weak, UDP-competitive antagonist of the pyrimidinergic receptor P2RY 14 with a naphthoic acid core was identified through high-throughput screening. Optimization provided compounds with improved potency but poor pharmacokinetics. Acylglucuronidation was determined to be the major route of metabolism. Increasing the electron-withdrawing nature of the substituents markedly reduced glucuronidation and improved the pharmacokinetic profile. Additional optimization led to the identification of compound 38 which is an 8 nM UDP-competitive antagonist of P2Y14 with a good pharmacokinetic profile.